Singapore's S*BIO Moving JAK2 Inhibitor Into Phase II In Early 2010
This article was originally published in The Pink Sheet Daily
Executive Summary
S*BIO's collaboration with Onyx for two JAK2 inhibitors was one of the biggest biotech deals in Asia; data on one compound presented at ASH.